Alpha 2.0
Login Register
» Articles » PMID: 39208200

COVID-19 IgG Seropositivity and Its Determinants in Occupational Groups of Varying Infection Risks in Two Andean Cities of Ecuador Before Mass Vaccination

Overview
Journal PLoS One
Specialties General Medicine
Science
Date 2024 Aug 29
PMID 39208200
Authors
Jose E Leon-Rojas
Fernanda Arias-Erazo
Patricia Jimenez-Arias
Ricardo Recalde-Navarrete
Angel Guevara
Josefina Coloma
Miguel Martin
Irina Chis Ster
Philip Cooper
Natalia Romero-Sandoval
Affiliations
Soon will be listed here.
Abstract

Background: The COVID-19 pandemic has caused over 68.7 million infections and 1.35 million deaths in South America. There are limited data on SARS-CoV-2 seropositivity and its determinants from Andean countries prior to mass vaccinations against COVID-19.

Objective: To estimate SARS-CoV-2 seropositivity and its determinants before vaccination in occupational groups of adults presumed to have different levels of exposure and associations with potential symptomatology.

Methods: We measured seropositivity of anti-SARS-CoV-2 IgG antibodies in a cross-sectional study of vaccine-naïve adults aged 18 years and older, recruited within three occupational risk groups (defined as low [LR], moderate [MR], and high [HR]) between January and September 2021 in two Andean cities in Ecuador. Associations with risk factors were estimated using logistic regression.

Results: In a sample of 882 adults, IgG seropositivity for the three different occupational risk groups was 39.9% (CI 95% 35.3-44.6), 74.6% (CI 95% 66.4-81.4), and 39.0% (CI 95% 34.0-44.4) for the HR, MR, and LR groups, respectively. History of an illness with loss of taste and/or smell was significantly associated with seropositivity in all occupational groups, with adjusted ORs of 14.31 (95%CI, 5.83-35.12; p<0.001), 14.34 (95%CI 3.01-68.42; p<0.001), and 8.79 (95%CI 2.69-28.72; p<0.001), for the HR, MR, and LR groups, respectively; while fever was significant for the LR group with an adjusted OR of 1.24 (95%CI, 1.11-4.57; p = 0.025) and myalgia for the HR group with an adjusted OR of 2.07 (95%CI, 1.13-3.81; p = 0.019).

Conclusion: Notable proportions of seropositivity were seen in all occupational groups between January and September 2021 prior to mass vaccination. Loss of taste and/or smell was strongly associated with presence of anti-SARS-CoV-2 IgG antibodies irrespective of presumed occupational exposure risk.

References
1.
Yang J, Ma L, Guo L, Zhang T, Leng Z, Jia M . Seroprevalence and dynamics of anti-SARS-CoV-2 antibodies: a longitudinal study based on patients with underlying diseases in Wuhan. Respir Res. 2022; 23(1):188. PMC: 9284953. DOI: 10.1186/s12931-022-02096-5. View
2.
Concha G, Frickmann H, Oey A, Strengert M, Kreienbrock L, Kann S . Direct and Indirect Proof of SARS-CoV-2 Infections in Indigenous Wiwa Communities in North-Eastern Colombia-A Cross-Sectional Assessment Providing Preliminary Surveillance Data. Vaccines (Basel). 2021; 9(10). PMC: 8539650. DOI: 10.3390/vaccines9101120. View
3.
Guevara A, Vivero S, Nipaz V, Guaraca V, Coloma J . A Low-Cost SARS-CoV-2 rRBD ELISA to Detect Serostatus in Ecuadorian Population with COVID-19. Am J Trop Med Hyg. 2021; 104(4):1513-1515. PMC: 8045656. DOI: 10.4269/ajtmh.20-1420. View
4.
Lanata C, Gil A, Ecker L, Cornejo R, Rios S, Ochoa M . SARS-CoV-2 infections in households in a peri-urban community of Lima, Peru: A prospective cohort study. Influenza Other Respir Viruses. 2021; 16(3):386-394. PMC: 8983893. DOI: 10.1111/irv.12952. View
5.
Tong J, Wong A, Zhu D, Fastenberg J, Tham T . The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2020; 163(1):3-11. DOI: 10.1177/0194599820926473. View